BACKGROUND: The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a prospective, observational cohort designed to assess the long-term safety of biologic and conventional systemic therapies used for adults with moderate-severe psoriasis in the UK and Republic of Ireland. OBJECTIVES: To describe the demographics, disease severity and co-morbidities of psoriasis patients on enrolment into BADBIR, and to highlight differences in those commencing biologic compared to conventional systemic therapies.
METHOD: Baseline data were collected from 151 Dermatology departments in the UK and Republic of Ireland. Descriptive analysis was conducted.
RESULTS: As of August 2014, 8399 patients were registered with BADBIR; 5065(60%) received biologics of whom 52.8% received adalimumab, 24.6% etanercept, 18.7% ustekinumab and 3.9% infliximab. In the comparator cohort 44.1% received methotrexate, 23.1% ciclosporin, 18.0% acitretin and 7.6% fumaric acid esters. 4897(58%) were male. Patients on biologics had a higher mean (±SD) age and disease duration than patients on conventional systemic therapies (46.3±12.7vs.44.3±14.3 years; 23.0±12.6vs.19.0±13.4 years, respectively; p1 co-morbidity. The most frequent co-morbidities were obesity (42.1%), hypertension (25.7%), depression (22.1%) and psoriatic arthritis (17.1%).
CONCLUSION: BADBIR is an invaluable resource to study the safety and effectiveness of both biologic and conventional systemic therapies. Understanding differences in baseline characteristics between cohorts is crucial in undertaking future pharmacovigilance studies. This article is protected by copyright. All rights reserved.